To evaluate the CSF‐1 receptor inhibitory properties of DBLZ compared to BLZ, treatments were assessed in vitro in BV2 microglia stimulated with interleukin‐4 (IL4), a TAMs activator that correlates with tumor prognoses.26 The gene discussed is IL4; the disease is neoplasm.